



**Date: 18th February 2020**

**Sydney, Australia**

## **Termination of Convertible Loan**

**Sydney, 18th February 2020:** Noxopharm (ASX: NOX) announces termination of its convertible loan facility.

On 12<sup>th</sup> February 2020 Noxopharm issued buy back and termination notices to The Lind Partners, LLC and CST Investment Funds (the lenders) in relation to company's existing convertible notes.

Noxopharm has today paid a total of \$4.085m to reduce the convertible loan balance to zero. The lenders exercised their right under the convertible loan agreement to convert \$575,000 of convertible loan balance into shares. Noxopharm has today issued 2.94m shares to the lenders in respect of this conversion.

Noxopharm appreciates the support of The Lind Partners, LLC and CST Investment Funds for providing this bridging finance arrangement. With the company now entering a pre-commercial high growth stage, the company considers it more appropriate to access traditional equity funding arrangements.

### **About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda<sup>®</sup> and is the major shareholder in non-oncology drug development company, Nyrada Inc. (ASX:NYR)

[www.noxopharm.com](http://www.noxopharm.com)

#### **Investor & Corporate Enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

#### **Company Secretary:**

David Franks  
T: +61 2 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

#### **Media queries:**

Catherine Strong  
Citadel-MAGNUS  
T: 02 8234 0111  
E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)



*Graham Kelly, CEO and Chairman of Noxopharm has approved the release of this document to the market.*

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.